What is the 13F Pro Quality Score for GRCE?

13F Pro ranks Grace Therapeutics, Inc. (GRCE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GRCE's current score at https://13fpro.ai/research/GRCE (free sign-up required for the full ranking).

Where does 13F Pro source GRCE data?

All Grace Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Grace Therapeutics, Inc. files with the SEC under CIK 1444192. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GRCE in?

Grace Therapeutics, Inc. (GRCE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is GRCE research updated on 13F Pro?

GRCE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Grace Therapeutics, Inc.(GRCE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1444192 GRCE stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 35 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

GRCE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Grace Therapeutics, Inc. (GRCE), a Healthcare sector company. GRCE is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 35 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q4 2026), Grace Therapeutics, Inc. reports net income of $-1.2M, free cash flow of $-1.7M. Top institutional holders of GRCE by reported 13-F value include Cerity Partners, Eversept Partners,, Nantahala Capital Management,, based on the most recent SEC filings. GRCE trades on the Nasdaq exchange and files with the SEC under CIK 1444192. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GRCE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Grace Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q4 2026

$-1.2M

Free Cash Flow

Q4 2026

$-1.7M

ROIC

Q4 2026

-4.7%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2026

FY23 —FY24 —FY25 —FY26 —

Net Income

+18.6% YoY

$-7.8MFY 2026

FY23 $-42.4MFY24 $-12.9MFY25 $-9.6MFY26 $-7.8M

Operating Income

+33.6% YoY

$-11.1MFY 2026

FY23 $-52.2MFY24 $-12.9MFY25 $-16.7MFY26 $-11.1M

EPS (Diluted)

+40.5% YoY

$-0.47FY 2026

FY23 $-5.71FY24 $-1.35FY25 $-0.79FY26 $-0.47

Total Assets

-7.4% YoY

$66.7MFY 2026

FY23 $79.1MFY24 $73.3MFY25 $72.0MFY26 $66.7M

Op. Cash Flow

+40.5% YoY

$-8.9MFY 2026

FY23 $-15.9MFY24 $-12.3MFY25 $-14.9MFY26 $-8.9M

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	—	—	—	—	$100.0M +50920.4%	$196.0K
Net Income	$-7.8M +18.6%	$-9.6M +25.6%	$-12.9M +69.7%	$-42.4M -332.1%	$-9.8M +50.1%	$-19.7M
Operating Income	$-11.1M +33.6%	$-16.7M -29.8%	$-12.9M +75.4%	$-52.2M -234.6%	$-15.6M +5.1%	$-16.4M
EPS (Diluted)	$-0.47 +40.5%	$-0.79 +41.5%	$-1.35 +76.4%	$-5.71 -2014.8%	$-0.27	—
Total Assets	$66.7M -7.4%	$72.0M -1.8%	$73.3M -7.4%	$79.1M -38.5%	$128.6M +105.9%	$62.5M
Operating Cash Flow	$-8.9M +40.5%	$-14.9M -20.8%	$-12.3M +22.5%	$-15.9M +7.7%	$-17.2M -20.4%	$-14.3M

AI Insight: GRCE Financial Trends

Grace Therapeutics burning cash at a modest but persistent clip with no revenue visibility and volatile equity base.

• Operating cash burn narrowed from $4M in Q2 2024 to $2M in Q4 2025 and Q1 2026, suggesting cost discipline.

• Net losses remain small and stable ($1M–$4M per quarter) but no revenue line disclosed across eight quarters.

• Equity fluctuated between $52M (Q4 2024) and $67M (Q1 2025), now at $64M in Q1 2026 — no clear trajectory.

⚠ Absence of revenue data across all periods; preclinical/early-stage biotech profile carries binary outcome risk.

⚠ Operating income remains negative every quarter; path to profitability and cash flow breakeven undefined.

AI Insight: GRCE Ratio Trends

Grace Therapeutics remains unprofitable across all metrics, with ROIC deteriorating to -18.8% in Q1 2026 after briefly stabilizing in late 2025.

• ROE and ROA showed modest sequential improvement from Q4 2025 (−14.3% and −13.5%) to Q1 2026 (−7.4% and −7.1%), but gains remain marginal.

• ROIC worsened from −15.1% in Q4 2025 to −18.8% in Q1 2026, undoing three consecutive quarters of gradual improvement.

⚠ Q1 2025 posted the only positive ROE (3.8%) and ROA (3.5%) in 18+ months; reversion to negative returns Q2–Q3 2025 suggests non-repeatable one-off benefit.

⚠ Persistent negative returns across ROE, ROA, and ROIC with no clear stabilization trajectory; TTM ROIC (−17.3%) indicates structural profitability challenge.

Get alerted when GRCE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Grace Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GRCE

Cerity Partners LLC
$3.9M849,055 sh
Eversept Partners, LP
$3.5M756,600 sh
Nantahala Capital Management, LLC
$3.4M728,203 sh
BANK OF AMERICA CORP /DE/
$2.3M494,723 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.9M401,656 sh
RENAISSANCE TECHNOLOGIES LLC
$1.1M243,910 sh
JANE STREET GROUP, LLC
$773.7K167,097 sh
CITADEL ADVISORS LLC
$457.2K98,742 sh
MARSHALL WACE, LLP
$423.3K91,416 sh
Connective Capital Management, LLC
$391.5K84,549 sh

Fund	Value	Shares
Cerity Partners LLC	$3.9M	849,055
Eversept Partners, LP	$3.5M	756,600
Nantahala Capital Management, LLC	$3.4M	728,203
BANK OF AMERICA CORP /DE/	$2.3M	494,723
VANGUARD CAPITAL MANAGEMENT LLC	$1.9M	401,656
RENAISSANCE TECHNOLOGIES LLC	$1.1M	243,910
JANE STREET GROUP, LLC	$773.7K	167,097
CITADEL ADVISORS LLC	$457.2K	98,742
MARSHALL WACE, LLP	$423.3K	91,416
Connective Capital Management, LLC	$391.5K	84,549

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put GRCE on your watchlist

Track score changes the day Grace Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is GRCE a good stock to buy?

13F Pro's AI-powered analysis of Grace Therapeutics, Inc. (GRCE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GRCE are available on the GRCE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own GRCE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GRCE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Grace Therapeutics, Inc.'s investment landscape.